Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBD for prevention of CIPN in patients receiving oxaliplatin or paclitaxel
NCT04582591Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Countries
- 1
- Sponsor
- Zealand University Hospital
- Drugs
- cannabidiol
- Conditions
- chemotherapy-induced peripheral neuropathy (CIPN)
01
Overview
Phase 2, open-label trial of cannabidiol in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Zealand University Hospital. Primary endpoint: Difference in Acute Neuropathic Symptoms from baseline and during 1. course chemotherapy at 5 days. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adult cancer patients scheduled for paclitaxel or oxaliplatin chemotherapy who have not previously received these agents and are not taking prohibited medications like Clobazam or strong CYP inducers.
04
Endpoints
Primary
Difference in Acute Neuropathic Symptoms from baseline and during 1. course chemotherapy
Beyond the preview
Go deeper on NCT04582591.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582591.